Table 1.

Individual patient characteristics

PatientAge, ySexDiagnosisTime from diagnosis to starting ponatinib, moPonatinib dose (OD), mgBest responseAdverse eventTiming of adverse eventIntervention
1 35 Male CML-AP; T315I mutation 48 30 CHR Coronary artery disease (triple-vessel disease) on evaluation for dyspnea; underwent CABG 5 mo after ponatinib Ponatinib stopped 
2 72 Male CML-AP; T315I mutation 16 15 CHR Thrombocytopenia (grade 4) 2 mo after ponatinib Intermittent discontinuation and dose reduction† of ponatinib 
3 34 Male CML-AP; T315I mutation 73 30 CHR Thrombocytopenia (grade 4) 1 mo after ponatinib Intermittent discontinuation and dose reduction† of ponatinib 
4 35 Male CML-CP; F317L mutation 121 30 CHR Thrombocytopenia (grade 3) 1 mo after ponatinib Ponatinib continued 
5 55 Female CML-CP; T315I mutation 90 30 MMR Skin rash, small vessel vasculitis on skin biopsy 1 mo after ponatinib Intermittent discontinuation and dose reduction† of ponatinib 
6 65 Female CML-CP 43 30 CHR Skin rash 2 mo after ponatinib Ponatinib continued with oral prednisolone 
7* 58 Male CML-CP; T315I mutation 99 45 CHR Peripheral vascular disease, coronary artery disease. Died from heart failure 4 mo after ponatinib Ponatinib stopped 
8 43 Male CML-AP; T315I mutation 156 30 CHR Thrombocytopenia (grade 4), skin rash 2 mo after ponatinib Intermittent discontinuation and dose reduction† of ponatinib 
9* 47 Female CML-AP; T315I mutation 80 30 MMR Desquamating skin rash. Died from acute coronary event. Skin rash after 2 mo of ponatinib, cardiac event after 6 mo of ponatinib Intermittent discontinuation and dose reduction† of ponatinib after skin rash 
10 35 Male CML-CP 48 45 MMR Thrombocytopenia (grade 3), skin rash 7 mo after ponatinib Ponatinib continued 
11 38 Male CML-CP; T315I mutation 64 45 MMR — — — 
12 38 Male CML-BC 15 45 CHR Thrombocytopenia (grade 4) 4 mo after ponatinib Ponatinib continued 
13 35 Male CML-CP; T315I mutation 10 45 MMR — — — 
14 35 Female CML-CP; T315I mutation 110 15 CHR Thrombocytopenia (grade 4) 1 mo after ponatinib Ponatinib continued 
15 37 Male CML-CP; F311L mutation 126 45 CHR Thrombocytopenia (grade 1) 2 mo after ponatinib Ponatinib continued 
16 32 Male CML-BC 43 45 CHR Thrombocytopenia (grade 1) 1 mo after ponatinib Ponatinib continued 
17 39 Female CML-AP; T315I mutation 99 45 CHR Thrombocytopenia (grade 4) 2 mo after ponatinib Ponatinib continued 
18* 47 Male CML-AP; T315I mutation 126 45 CHR Thrombocytopenia (grade 4), skin rash, venous thromboembolism. Died from progressive disease. 4 mo after ponatinib Intermittent discontinuation of ponatinib 
19 60 Male CML-CP; T315I mutation 39 45 CHR — — — 
20 39 Male CML-BC; T315I mutation 23 30 CHR not achieved Pancreatitis 1 mo after ponatinib Intermittent discontinuation of ponatinib 
PatientAge, ySexDiagnosisTime from diagnosis to starting ponatinib, moPonatinib dose (OD), mgBest responseAdverse eventTiming of adverse eventIntervention
1 35 Male CML-AP; T315I mutation 48 30 CHR Coronary artery disease (triple-vessel disease) on evaluation for dyspnea; underwent CABG 5 mo after ponatinib Ponatinib stopped 
2 72 Male CML-AP; T315I mutation 16 15 CHR Thrombocytopenia (grade 4) 2 mo after ponatinib Intermittent discontinuation and dose reduction† of ponatinib 
3 34 Male CML-AP; T315I mutation 73 30 CHR Thrombocytopenia (grade 4) 1 mo after ponatinib Intermittent discontinuation and dose reduction† of ponatinib 
4 35 Male CML-CP; F317L mutation 121 30 CHR Thrombocytopenia (grade 3) 1 mo after ponatinib Ponatinib continued 
5 55 Female CML-CP; T315I mutation 90 30 MMR Skin rash, small vessel vasculitis on skin biopsy 1 mo after ponatinib Intermittent discontinuation and dose reduction† of ponatinib 
6 65 Female CML-CP 43 30 CHR Skin rash 2 mo after ponatinib Ponatinib continued with oral prednisolone 
7* 58 Male CML-CP; T315I mutation 99 45 CHR Peripheral vascular disease, coronary artery disease. Died from heart failure 4 mo after ponatinib Ponatinib stopped 
8 43 Male CML-AP; T315I mutation 156 30 CHR Thrombocytopenia (grade 4), skin rash 2 mo after ponatinib Intermittent discontinuation and dose reduction† of ponatinib 
9* 47 Female CML-AP; T315I mutation 80 30 MMR Desquamating skin rash. Died from acute coronary event. Skin rash after 2 mo of ponatinib, cardiac event after 6 mo of ponatinib Intermittent discontinuation and dose reduction† of ponatinib after skin rash 
10 35 Male CML-CP 48 45 MMR Thrombocytopenia (grade 3), skin rash 7 mo after ponatinib Ponatinib continued 
11 38 Male CML-CP; T315I mutation 64 45 MMR — — — 
12 38 Male CML-BC 15 45 CHR Thrombocytopenia (grade 4) 4 mo after ponatinib Ponatinib continued 
13 35 Male CML-CP; T315I mutation 10 45 MMR — — — 
14 35 Female CML-CP; T315I mutation 110 15 CHR Thrombocytopenia (grade 4) 1 mo after ponatinib Ponatinib continued 
15 37 Male CML-CP; F311L mutation 126 45 CHR Thrombocytopenia (grade 1) 2 mo after ponatinib Ponatinib continued 
16 32 Male CML-BC 43 45 CHR Thrombocytopenia (grade 1) 1 mo after ponatinib Ponatinib continued 
17 39 Female CML-AP; T315I mutation 99 45 CHR Thrombocytopenia (grade 4) 2 mo after ponatinib Ponatinib continued 
18* 47 Male CML-AP; T315I mutation 126 45 CHR Thrombocytopenia (grade 4), skin rash, venous thromboembolism. Died from progressive disease. 4 mo after ponatinib Intermittent discontinuation of ponatinib 
19 60 Male CML-CP; T315I mutation 39 45 CHR — — — 
20 39 Male CML-BC; T315I mutation 23 30 CHR not achieved Pancreatitis 1 mo after ponatinib Intermittent discontinuation of ponatinib 

AP, accelerated phase; BC, blast crisis; CABG, coronary artery bypass graft surgery; CP, chronic phase.

*

Died during follow-up.

†

If on 15 mg, ponatinib was reduced to alternate days.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal